Aiming for systemic treatment through intravenous administration
Advancing to subsequent stages, including preclinical studies

SillaJen's next-generation oncolytic virus candidate, SJ-650, has been selected for a government-funded drug development project. With this support, SillaJen plans to develop a manufacturing process and advance the candidate into the preclinical stage.


SillaJen's Oncolytic Virus Candidate 'SJ-650' Selected for National Project for Drug Development View original image


On November 18, SillaJen announced that SJ-650 had been selected for a project under the National Project for Drug Development, overseen by the Korea Drug Development Fund. The National Project for Drug Development is a pan-government research and development (R&D) initiative aimed at strengthening the global competitiveness of South Korea's pharmaceutical and biotech industries. It supports the entire drug development cycle for 10 years, starting in 2021.


SJ-650 is a candidate being developed for systemic treatment through intravenous administration. The therapeutic effects of intravenous oncolytic viruses can be limited by complement proteins and neutralizing antibodies in the blood. To overcome this, SJ-650 has been designed to express human CD55 protein on the surface of the virus. The approach focuses on enabling the virus to reach tumors reliably, even in the immune environment of the bloodstream.


Through this approach, SillaJen aims to overcome limitations on systemic and repeated administration, which have been cited as shortcomings of existing oncolytic virus therapies, and expand the treatment scope to include not only primary cancers but also metastatic cancers. The research findings are scheduled to be published in Molecular Therapy, the official journal of the American Society of Gene and Cell Therapy (ASGCT).


SillaJen will proceed in stages with subsequent work, including preclinical safety assessments and the development of raw materials, manufacturing, and quality control (CMC). It also plans to explore opportunities for joint development and technology licensing with global pharmaceutical companies.



A SillaJen representative said, "Being selected for this project is significant because it will allow us to advance research and development of SJ-650 in earnest. We will proceed with candidate identification and manufacturing process development without delays, laying the groundwork for entry into the next stage."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing